New Biotech Company Lyora Therapeutics Aims to Tackle Inherited Retinal Diseases
The inherited retinal disease (IRD) community has a new player in the biotech landscape: Lyora Therapeutics. The company officially launched with a focus on developing genetic medicines to address the root causes of IRDs, conditions that often lead to progressive vision loss and currently lack available treatments. This news offers a potential source of hope for patients and families seeking new therapeutic options for these challenging diseases.
Lyora Therapeutics has launched with seed funding and a leadership team, aiming to advance a pipeline of biologically validated therapies through clinical development. The company's approach centers on